Additionally, we observed that AFAP1-AS1 lowers the efficacy of the maximum dose of cisplatin, 5-FU, and paclitaxel drugs at 24 h in 162 ESCC patients [58]. Here, AFAP1 is linked to esophageal squamous cell carcinoma.